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Background: Development of new tinnitus treatments requires prospective placebo-controlled randomized trials to
prove their efficacy. The Tinnitus Questionnaire (TQ) is a validated and commonly used instrument for assessment
of tinnitus severity and has been used in many clinical studies. Defining the Minimal Clinically Important Difference
(MCID) for TQ changes is an important step to a better interpretation of the clinical relevance of changes observed
in clinical trials. In this study we aimed to estimate the minimum change of the TQ score that could be considered
clinically relevant.
Methods: 757 patients with chronic tinnitus were pooled from the TRI database and the RESET study. An anchor-
based approach using the Clinical Global Impression (CGI) scale and distributional approaches were used to
estimate MCID. Receiver Operating Characteristic (ROC) curves were calculated to define optimal TQ change cutoffs
discriminating between minimally changed and unchanged subjects.
Results: The relationship between TQ change scores and CGI ratings of change was good (r = 0.52, p< 0.05). Mean
change scores associated with minimally better and minimally worse CGI categories were −6.65 and +2.72
respectively. According to the ROC method MCID for improvement was −5 points and for deterioration +1 points.
Conclusion: Distribution and anchor-based methods yielded comparable results in identifying MCIDs. ΔTQ scores
of −5 and +1 points were identified as the minimal clinically relevant change for improvement and worsening
respectively. The asymmetry of the MCIDs for improvement and worsening may be related to expectation effects.
Keywords: Tinnitus, Tinnitus questionnaire, Minimal clinically important difference, Clinical significance, Receiver
operating characteristicBackground
Subjective tinnitus is a frequent sensation of sound that
cannot be attributed to an external sound source [1,2].
Treatment of tinnitus is difficult and for most of the cur-
rently used treatment strategies the evidence of efficacy
is low [3]. Many interventions in reducing tinnitus-
related distress are based on cognitive theories of behav-
ior regulation and on psychological treatments [4,5]. In
recent years animal models and neuroimaging of tinnitus
perception have contributed to substantial advances in* Correspondence: i adamchic@fz-juelich.de
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reproduction in any medium, provided the orthe understanding of the pathophysiology of tinnitus
[2,6–8], which in turn has prompted the development of
new treatment strategies [4,9–11]. For assessing the effi-
cacy of the various tinnitus treatment strategies, pro-
spective placebo-controlled randomized trials have to be
performed. An important aspect in the design of such
clinical trials is the choice of the outcome measure.
However in tinnitus research, the quantification of tin-
nitus severity can be challenging for several reasons.
First, tinnitus is a purely subjective phenomenon and
lacks any objectively identifiable variables or markers.
Second, taking into account that tinnitus affects many
different aspects of well-being (i.e., sleep, mood,ral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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bothered by some symptoms and less by others [12].
In the evaluation of new treatments for tinnitus, sev-
eral instruments are used to provide a quantification of
tinnitus symptoms [13]. The TQ is a widely used ques-
tionnaire for the quantification of tinnitus complaints.
Developed by Hallam et al. [14], it has been translated
and validated in German language [15] and is widely
used in the German version. The TQ incorporates scales
evaluating emotional and cognitive distress, intrusive-
ness, auditory perceptual difficulties, sleep disturbances,
and associated somatic complaints. It was recom-
mended, among other validated questionnaires, such as
Tinnitus Handicap Inventory (THI) [4], Tinnitus Handi-
cap Questionnaire (THQ) [16], and Tinnitus Reaction
Questionnaire (TRQ) [17], in a consensus document of
the Tinnitus Research Initiative (TRI) to be used as an
outcome measurement in clinical trials [13]. It has also
been used, in isolation or in conjunction with other tin-
nitus questionnaires, for assessing the effect of various
therapeutic interventions in many clinical studies on
chronic tinnitus [9,18–20].
When using health status questionnaires to ascertain
whether a treatment for a given condition is effective or
not, statistical significance of effects is usually reported.
Statistically significant effects are those that are beyond a
certain level of chance. However, noteworthy statistical sig-
nificance of a treatment effect largely depends on the sam-
ple size and does not provide information of whether
observed changes are clinically meaningful. In contrast,
clinical relevance of a treatment effect refers to its impact
upon the patient, to its implications for management of
the patient, to its ability to meet standards of efficacy set
by patients, clinicians, and researchers [21,22]. The ques-
tion of what is the clinical meaning of the reported score
change usually remains open [21–23]. Thus, deriving clin-
ical meaning from statistically significant results may be
misleading. Results of clinical studies for tinnitus usually
report changes in TQ scores as continuous variables for
each group [24] (e.g., mean change or Effect Size (ES) for
each group) and thus are difficult to interpret when trans-
lated to the level of clinical relevance and an individual re-
sponse. Therefore, exact knowledge about which change of
the TQ is clinically relevant is critical, both for the design
and interpretation of a clinical trial as well as for rational
decision-making in clinical management of tinnitus
patients. In order to estimate meaningfulness of changes in
clinical scores, the concept of the Minimal Clinically Im-
portant Difference has been developed [25,26]. The MCID
for a given questionnaire score can be defined as the value
above which the change becomes clinically relevant.
However, no consensus exists on the methods that should
be used in estimating the MCID [25]. Techniques used in
MCID evaluation are usually divided in two groups:distribution- and anchor-based. Distribution-based methods
use statistical properties of a study's results, e.g., ES, Standard
Error of Measurement (SEM) and other measures obtained
from characteristics of study population [21–23,27,28]. In
anchor-based methods changes in used measuring instru-
ment (e.g., patient reported outcomes, PRO) are referenced
to an anchor [21,25,26,29], which should reflect the patient’s
perspective [30]. This is especially relevant for a purely
subjective condition such as tinnitus [31].
Given that tinnitus is a purely subjective condition a
patient-rated CGI seems more appropriate as a judgment
for the change of tinnitus-related global impairment than
a CGI of a rater, based on an interview. Accordingly, sev-
eral recent clinical trials used a patient-rated CGI change
as outcome criterium [32,33]. Therefore, patient-rated
CGI scales represent a valid example of a reference anchor
[26,34,35]. Anchor based methods were recommended as
primary methods for MCID estimation complemented by
various distribution-based estimates (e.g., ES and SEM) as
supportive information [25,36,37].
It has been implied in the available literature that the
magnitude of a meaningful score change may be inde-
pendent of the direction of change, i.e., MCID for im-
provement (MCID-I) is equivalent to the MCID for
deterioration (MCID-D) [26,38]. However, clinical experi-
ence and previous studies challenge this assumption
[37,39]. Thus MCID can be bidirectional and can differ-
ently reflect an improvement and deterioration. It has
been observed in studies in tinnitus and chronic pain
patients that a smaller change in measuring instrument
scores is sufficient to feel deterioration than the change
needed to feel improvement [31,39,40]. In contrast studies
in cancer patients showed the opposite. Small improve-
ments were considered relevant by patients whereas
declines have to be large to be perceived as worsening
[37,41].
The aim of this study was to determine which change
in the TQ score is considered as a meaningful clinical
change with the main aim to identify the minimal score
reduction which is perceived as improvement (MCID-I)
[37,39]. We defined MCID as the smallest change in the
measurement instrument used that signifies a percep-
tible improvement or deterioration in tinnitus from the
patient’s perspective. To estimate clinically relevant
changes, we analyzed data from the TRI database [42] and
from the RESET study [43]. We compared changes in the
TQ with patient’s subjective evaluation of treatment-
related changes of tinnitus assessed with the Clinical
Global Impression Change scale.
Methods
Patients
Data from the RESET study (ClinicalTrials.gov Identifier:
NCT00927121) [43] combined with data from the TRI
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longitudinal data collected in a standardized way from
tinnitus patients undergoing different types of treatment
interventions in different study centers and different
countries. Collection of data for the TRI database was
approved by the local ethics committee of the University
of Regensburg, Germany. The RESET study was a multi-
centric randomized, controlled clinical trial on acoustic
CR neuromodulation in the treatment of chronic tin-
nitus, performed in Germany between 2009 and 2010,
ethical committee approved the trial design and all
changes.
757 patients (694 from the TRI database and 63 from
the RESET study) from 7 different centers in Germany
who had received different forms of tinnitus treatment,
including acoustic coordinated reset neuromodulation,
transcranial magnetic stimulation, behavioral therapy
and pharmacologic treatment were included in the ana-
lysis. Data for every patient included the TQ at baseline,
TQ and CGI at outpatient visits and at the end of treat-
ment. The number of visits between the begin and the
end of treatment was 1 for 112 patients, 2 for 74
patients, 3 for 151 patients, 4 for 29 patients, 5 for 134
patients and 6 for 257 patients (total 3041 visits). The
mean time between baseline and assessment was 44
days.
Questionnaires and scales
Tinnitus severity was assessed with the German version
of the Tinnitus Questionnaire [15]. The German version
of the TQ consists of 52 questions and the total sum
score ranges from 0 (no distress) to 84 (very severe dis-
tress). The total score is based on 42 questions out of 52
and two question is included twice. This questionnaire
indicates the general level of tinnitus related psycho-
logical and psychosomatic distress. Factor analysis of the
German version of the TQ revealed the factors emo-
tional and cognitive distress, intrusiveness, auditory per-
ceptual difficulties, sleep disturbances, and associated
somatic complaints. According to its total score, the TQ
is divided in four distress levels: mild (0–30), moderate
(31–46), severe (47–59), very severe (60–84) [15].
Patient-rated global assessment of treatment effects
was performed in all patients of this study. In the RESET
study, a custom designed Clinical Global Impression
(CGI) score was used. In this CGI at each visit, patients
were asked to give a verbal categorical rating of their tin-
nitus loudness and annoyance for each ear where tin-
nitus was perceived as compared to baseline. Patients
had 5 choices: 1 =much better; 2 = somewhat better;
3 = no change; 4 = somewhat worse, or 5 =much worse.
CGI was side specific. Patients were not permitted to
refer to any previous markings. Reduction of subjectively
perceived tinnitus loudness and reduction of tinnitusannoyance were shown to be highly correlated [43,44].
Furthermore, a robust correlation between the reduction
of tinnitus loudness and reduction of TQ scores was
reported [43]. Therefore, at each visit the mean score of
all CGI values (from both sides, in case of bilateral tin-
nitus, and from both domains: loudness and annoyance)
served as the summary global rating of change for each
patient.
A CGI-I was applied in the studies included in the TRI
database, to assess a patient’s subjective perception about
the change of tinnitus over time [31]. Patients had to mark
1 of the 7 answers: 1 = very much better; 2 =much better;
3 =minimally better; 4 = no change; 5 =minimally worse;
6 =much worse, and 7= very much worse. In both, the
TRI database and the RESET study, the patients were
asked to “rate the improvement of their tinnitus com-
plaints compared to before the beginning of treatment”.
For better applicability across TRI database and the
RESET study we combined “very much better” and
“much better” categories of the CGI-I used in the TRI
database into a “much better” as well as “much worse”
and “very much worse” in to a “much worse” categories.
In addition CGI-I categorical numeration of the CGI-I
used in the TRI database was changed to be in accord-
ance with the 5 level CGI similar to the one used in the
RESET study.
For analysis, different groups were formed according
to the CGI scores:
Much better: CGI = 1
Minimally better: CGI = 2
No change: CGI = 3
Minimally worse: CGI = 4
Much worse: CGI = 5
Statistical analysis
TQ change from baseline was determined by subtracting
the value at visit from baseline value. Thus, negative TQ
change value meant a reduction of tinnitus. A one-way
analysis of variance (ANOVA) of the TQ changes was
conducted to test for significant differences between
CGI levels. To compare 2 continuous variables, the t-
test for independent or dependent variables was used.
All tests were two-tailed and exploratory, i.e., no adjust-
ments for multiple comparisons were performed and a
p< 0.05 was considered statistically significant. Missing
data were not replaced. MCID calculations should be
based on the patient-reported outcomes, e.g., TQ, that
are correlated at r ≥ 0.30 with appropriate patient based
or clinical anchors, e.g., CGI [45]. Thus we assessed the
usefulness of the used anchor (i.e., CGI) by calculating
the Spearman rank correlation of CGI scores with the
absolute and relative ((i.e., visit value-base line value)/
base line value) changes of the TQ scores for the
Table 1 Patient baseline characteristics (N= 757)
Age, years (SD) 50.8 (SD 12.4)
Tinnitus duration, years (SD) 7.5 (SD 8.0)
Gender, N (%)
Male 538 (71.1%)
Female 219 (28.9%)
Laterality of tinnitus N (%)
Right 92 (12.1%)
Left 145 (19.2%)
Bilateral/inner head 520 (68.7%)
TQ at baseline, Mean (SD) 42.0 (SD 16.9)
Tinnitus severity at baseline based
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used to determine test–retest reliability of the CGI in
patients whose TQ score change between two visits was
2 points or less in any direction. First and second visit
data from the TRI database and 8 and 12 weeks visit
data from the RESET study were used to calculate ICC.
To estimate the ES for TQ score changes at different
levels of CGI Cohen’s d was used. It was calculated using
the original standard deviations formula: d = (M1 – M2)/
SDpooled where M1 and M2 are the mean values of TQ at
baseline and visits, and SD pooled is the pooled standard
deviation for independent samples [27]. The Standard
Error of Measurement for the TQ was also computed:
SEM=SD
ffiffiffiffiffiffiffi
1−r
p
, where SD is the standard deviation of TQ
scores, and r is the test-retest reliability of the TQ, i.e., 0.94.
ROC curves were calculated to define cutoff values for
TQ changes that best distinguished those who had minim-
ally improved or minimally deteriorated from those who
had not changed [46,47]. A ROC TQ plot was produced by
plotting true positive rate, or sensitivity vs. 1-specificity or
false positive rate. Sensitivity was defined as the number of
patients correctly identified by selected measure or test, e.
g., TQ threshold, as changed divided by number of all
patients who truly underwent a change. Specificity was
defined as the number of patients who were correctly clas-
sified by the selected measure as not changed divided by
the number of all patients who truly did not undergo an
important change. The optimal amount of TQ change that
was used to discriminate between subjects rated as minim-
ally improved or minimally worse from subjects rated as
unchanged on the CGI was selected as corresponding to
the highest average of sensitivity and specificity. Statistical
analyses were performed in STATISTICA 8 software
(www.statsoft.com). The ROC statistic was calculated using
the method implemented in the commercially available
software MedCalc (www.medcalc.org). Positive likelihood
ratio was defined as ratio between sensitivity and
1-specificity. Negative likelihood ratio was defined as
ratio between 1-sensitivity and specificity.
To investigate the time course of mean TQ change in
the minimally better CGI level with time passed from
baseline we divided all visits in to 11 categories: 1–9,
10–19, 20–29, 30–39, 40–49, 50–59, 60–69, 70–79,
80–89, 90–99 and ≥ 100 days since baseline. For each of
the 11 categories a mean TQ change value in patients
who indicated “minimally better” on the CGI was calcu-
lated. In case that one patient had multiple observations
in one of the 11 periods, the mean value was calculated.on TQ, N (%)
Severe 136 (18.0%)
Moderate 170 (22.4%)
Mild 234 (30.9%)
Slight 217 (28.7%)
Abbreviations: SD, standard deviation.Results
757 patients from Germany, aged between 12 and 86
years, were included in this study; the mean tinnitus
duration was 7.5 years (min 2 months, max 44 years).751 patients suffered from chronic subjective tinnitus
(> 3 month) and 6 had tinnitus duration between 2
and 3 months. Baseline characteristics are presented in
Table 1. The average age of the patients was 50.8 (SD
12.4), and 71.1% of them were men. The mean baseline
score of the TQ was 42.0 (SD 16.9). The distribution of
the changes of the TQ scores, categorized by the CGI is
given in Figure 1. Number of patients in each treatment
category were as follows: transcranial direct current
stimulation 28, transcranial magnetic stimulation 562,
pharmacological treatment 35, CR neuromodulation 46,
noisy CR neuromodulation 12, placebo 37, transcutane-
ous vagus nerve stimulation 24, and for 13 patients
there was no record. GCI test-retest reliability was
found to be very good: ICCs for the seven item CGI
used in TRI database and five item CGI used in the RE-
SET study were 0.74 (95% CI 0.63/0.82) and 0.72 (95%
CI 0.36/0.87) respectively. We did not observe any con-
sistent trends indicating a progressive change of MCID
with time passed since baseline (Table 2). Based on this
observation all further analyses were performed on data
from the last outpatient visit for every patient.
One way ANOVA revealed significant differences be-
tween the TQ mean score changes across 5 CGI levels
(F = 79.5, p< 0.001). The distribution of TQ changes
and ES corresponding to each CGI category are sum-
marized in Table 3. The Spearman correlation coeffi-
cient between absolute TQ change and CGI was r = 0.52
(p< 0.001) and between relative TQ change and CGI was
r = 0.42 (p< 0.001). The minimally better group had a
mean TQ change of −6.65 (95% CI −7.90/-5.39) and an Ef-
fect Size of 0.41 (95% CI 0.18/0.63). The minimally worse
group had a mean TQ change of 2.72 (95% CI 0.95/4.49)
Figure 1 Boxplots of Tinnitus Questionnaire score changes from baseline categorized by the Clinical Global Impression. Median value,
1st and 3d quartile and the non-outlier range are shown.
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group had a mean change −0.33 (95% CI −1.19/0.54) that
was not significant as compared to baseline (p= 0.46).
It has been previously reported that MICD values are
dependent on baseline values (e.g., in patients with low
back pain) [48]. In Table 4 mean changes from the 5
CGI levels were classified according to the TQ baseline
score. Patients with higher TQ scores at baseline (indi-
cating more severe complaints), generally needed greater
reduction of the TQ to be classified as minimally im-
portantly improved based on the used anchor. For wor-
sening of tinnitus symptoms this seemed not to hold
true and even a slight opposite tendency was observed,Table 2 Mean TQ change in the minimally better CGI
level with time passed from baseline (no significant
differences neither clear trend)
Date range (days) Number Mean (SD)
1-9 119 −3.28 (6.26)
10-19 171 −4.87 (6.53)
20-29 130 −4.82 (7.74)
30-39 9 −9.67 (12.44)
40-49 1 −11.00 (N/A)
50-59 91 −5.32 (8.99)
60-69 14 −4.43 (9.75)
70-79 10 −6.00 (12.46)
80-89 103 −5.77 (7.23)
90-99 38 −7.68 (6.66)
≥ 100 10 −4.47 (7.19)i.e., patients with higher TQ scores at baseline, gener-
ally needed lower increase of the TQ score to feel min-
imally worse.
Table 5 provides specific threshold levels (optimal cut-
off points), generated from the ROC analyses for all
patients from the CGI minimally better change group
and for these patients grouped according to their base-
line TQ scores. The area under the ROC curve for all
TQ scores was 0.79 (95% CI 0.78-0.81) for minimally
better vs. no change groups (Figure 2) and 0.60 (95% CI
0.55-0.64) for minimally worse vs. no change groups.
The optimal amount of TQ change that was used to dis-
criminate between the minimally better group and the
no change group was −5 points and +1 point between
the minimally worse group and the no change group.
However, a relatively low area under the ROC curve
(0.60) as well as low sensitivity (56.30) and specificity
(61.34) values for the minimally worse group vs. the no
change group make these estimates less reliable then the
ones obtained for the minimally better group vs. the no
change group. These results also indicate that higher
threshold values were obtained for the patients with
higher TQ scores at baseline for the minimally better vs.
the no change group. The SEM was 4.2 points and was
slightly smaller than ROC based MCID-I estimate and
mean TQ change for symptoms reduction. An effect size
of d = 0.5 was proposed as a “universal” cut off point in
the interpretation of changes of quality-of-life data [49].
The mean pooled standard deviation of all data is 18.
With an estimated standard deviation of the before-after
difference of the TQ score = 18 the effect size of d = 0.5
can be calculated to be ΔTQ=9. Figure 3 provides a
Table 3 TQ characteristics of clinical global impression groups
CGI Number (%) ΔTQ,
Mean (SD)
95% CI of ΔTQ Cohen d 95% CI of d
Much better 79 (10.4) −16.73 (12.65) −19.57/-13.90 0.96 0.63/1.29
Minimally better 158 (20.9) −6.65 (7.99) −7.90/-5.39 0.41 0.18/0.63
No change 357 (47.2) −0.33 (8.30) −1.19/0.54 0.02 −0.13/0.17
Minimally worse 119 (15.7) 2.72 (9.76) 0.95/4.49 −0.14 −0.39/0.11
Much worse 44 (5.8) 6.20 (11.35) 2.75/9.66 −0.36 −0.78/0.06
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methods.
As the analysis was based on 2 datasets in which 2 dif-
ferent CGI questionnaires were used, we were interested
in how far this could have affected the results. Medians
of the CGI minimally better group were −7 and −6 for
the RESET and TRI datasets. Furthermore, CGI minim-
ally better groups from the RESET and TRI samples
were not significantly different (p = 0.18). Thus combin-
ing data from 2 datasets (i.e., TRI and RESET) is not
likely to have affected the final result.
Discussion
To improve the quality of tinnitus management and to
evaluate new tinnitus therapies validated tinnitus specific
questionnaires are used. The assessment of clinical signifi-
cance of changes in these questionnaires often poses the
biggest challenge in interpretation of obtained results. Be-
cause of its validity and reliability the TQ is a powerful tool
in the field of tinnitus research and management [13,15].
Moreover, its widespread use, especially in German speak-
ing countries, enables comparisons across clinical trials.
However no empirical data are available to judge which
minimal change is needed to be of clinical relevance. In
this study we addressed this issue by evaluating a MCID-I
and MCID-D for the TQ.
The data analyzed in this study come from a large co-
hort of patients that underwent various treatment inter-
ventions in different centers, ranging from primary to
tertiary referral centers. All patients were assessed with
similar measurement instruments and methodology. The
large dataset was collected in multiple centers including a
wide range of patients with different treatments; therefore,Table 4 Dependence of TQ change in CGI 2 on baseline value
CGI 0-30 31-46
N Mean (SD) N Mean
Much better 30 −8.47 (8.05) 18 −16.39
Minimally better 54 −3.17 (7.15) 46 −7.07 (
No change 111 0.98 (7.68) 118 0.29 (9.
Minimally worse 35 3.20 (9.10) 39 3.49 (9.
Much worse 7 12.86 (13.52) 13 7.23 (10it can be regarded as representative and the obtained
results can be generalized to other samples.
Techniques available for evaluating MCID are usually
divided in two groups: distribution- or anchor-based [21].
It has been recommended to estimate the MCID based on
several methods using relevant anchors complemented by
various distribution-based estimates (i.e., ES, SEM) as sup-
portive information, and then triangulate on a single value
or small range of values for the MCID based on all used
methods [36,37]. Accordingly, we used the CGI as the
self-assessment of the changes in tinnitus symptoms to in-
vestigate the size of a meaningful change in TQ score. Sig-
nificant association between patient’s global retrospective
rating and the actual change of TQ scores as shown by
correlation between these two instruments enabled a com-
parison of the two.
The smallest degree of meaningful change is repre-
sented by minimally worse and minimally better CGI
levels. Some studies de-emphasize an important dis-
tinction between improvement and worsening of
patient’s symptoms [26,38]. In observations rated as
minimally worse and minimally better mean changes
in TQ scores were consistent with the expected direc-
tion of change: ΔTQ +2.72 and −6.65 respectively.
These findings are also consistent with previously pub-
lished data on the other validated tinnitus question-
naire, i.e., Tinnitus Handicap Inventory [31]. Among
patients who reported a minimal worsening of their
tinnitus symptoms, average change scores on the TQ
were smaller then among patients who reported min-
imal improvement, indicating that it took a smaller
amount of TQ score increase for patients to perceive
their tinnitus as worse.47-59 60-84
(SD) N Mean (SD) N Mean (SD)
(10.09) 19 −24.95 (11.14) 12 −24.92 (15.05)
6.86) 42 −8.86 (9.02) 16 −11.38 (6.44)
03) 64 −0.56 (8.04) 64 −3.50 (7.51)
51) 22 2.23 (14.20) 23 1.17 (5.51)
.00) 15 5.00 (12.15) 9 1.56 (8.95)
Table 5 Test characteristics for best Tinnitus Questionnaire cutoff point for the minimally better group
TQ N minimally
better group
ROC MCID
Estimate
Area under
ROC Curve
(95% CI)
Sensitivity
(95% CI)
Specificity
(95% CI)
Positive likelihood
ratio (95% CI)
Negative likelihood
ratio (95% CI)
0-84 158 −5 0.79 (0.78-0.81) 71.43 (63.4/78.6) 73.10 (67.9/77.9) 2.66 (2.4/3.0) 0.39 (0.3/0.5)
0-30 54 −2 0.65 (0.61-0.68) 66.67 (52.5/78.9) 59.46 (49.7/68.7) 1.64 (1.3/2.1) 0.56 (0.4/0.9)
31-46 46 −3 0.74 (0.70-0.78) 80.43 (66.1/90.6) 60.17 (50.7/69.1) 2.02 (1.6/2.5) 0.33 (0.2/0.6)
47-59 42 −5 0.75 (0.71-0.79) 71.43 (55.4/84.3) 64.06 (51.1/75.7) 1.99 (1.5/2.6) 0.45 (0.2/0.8)
60-84 16 −12 0.80 (0.76-0.84) 62.50 (35.4/84.8) 89.06 (78.8/95.5) 5.71 (3.9/8.4) 0.42 (0.2/1.1)
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groups, i.e., ΔTQ −16.7 vs. +6.20 respectively, are con-
sistent with the changes in the minimally improved and
worsened groups in the sense that higher score changes
are needed for meaningful improvement than for sub-
jectively perceived worsening. Consistent with this asym-
metry is the finding that the group, that observed “no
change”, had an average improvement of −0.33 points in
the TQ. This response bias might reflect the anticipation
of improvement. With an expectation of improvement, a
small increase of symptoms is sufficient to be perceived
as worsening whereas the symptom reduction has to be
more pronounced, to be really perceived as relevant. An-
other general methodological concern of MCID estima-
tion is reliability of clinical global change ratings over
time as patients internal reference may change with time
or be influenced by recall bias [50]. In our study we
investigated, if the mean ΔTQ for minimally improved
patients changes in some consistent manner with time100
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Figure 2 Receiver Operating Characteristic curve. Plot represents
comparison of two operating characteristics, i.e., False-Positive Rate
and True-Positive Rate as the criterion of TQ change.passed since baseline. Our results showed that the mean
TQ change in the minimally better group during the
first 10 days after the baseline measurement did not dif-
fer from those made after 100 days passed since baseline.
Even though this study was not designed to investigate
changes of patient’s internal frame of reference with
time, our results do not show evidence of any consistent
changes of such an internal reference. Accordingly we
do not expect that longer or shorter intervals between
baseline and MCID assessment, as compared to mean
interval in this study, i.e., 44 days, could have resulted in
a significantly different MCID estimate. In this study, four
different MCID-I estimates were computed (Figure 3).
The strategy used in the ROC analysis for MCID estima-
tion was to maximize both sensitivity and specificity. The
results show that the MCID-I magnitude for all patients
combined was −5 TQ points. However, the magnitude of
a TQ change that was perceived by the patients as min-
imal reduction or worsening of tinnitus depended on
patients' baseline TQ scores (Tables 4 and 5). For example,
patients with high initial TQ scores needed to undergo an
improvement of approximately −12 TQ points in order
for the change to be judged important. Whereas for
patients with low TQ scores an improvement of −2 TQ
points suffices in order to be perceived as improvement.0
-2.5
-5.0
Effect size 0.5
SEM
ROC
Minimally better mean
-6.7
-5.0
-4.2
-9.0
QT
Δ
-7.5
-10.0
Figure 3 Summary of distribution- and anchor-based estimates
of MCID.
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http://www.hqlo.com/content/10/1/79There are 2 possible explanations for this trend. First,
it may be that more disabled patients were only satisfied
with greater reduction of tinnitus. It has been suggested
previously that the thresholds for change may shift de-
pending on initial symptoms severity and that smaller
improvements may mean more to the patients with mild
rather than severe disability [51,52]. Second, some
patients have achieved greatest possible reduction on
TQ score and no further effect on tinnitus was possible
– a so-called ”ceiling effect”. From the entire population
only one patient who reported minimally better achieved
minimal (zero) TQ score. This patient had a TQ change
of −3 points. No patient achieved maximal (eighty four)
TQ score. Both of these reasons probably contribute to
the finding that the MCID depends on the baseline tin-
nitus severity score. Unfortunately the magnitude of
contribution of each of these factors cannot be deter-
mined. MCID-I estimate based on the mean TQ change
of the minimally better group was around −6.65 points
and was very similar to the one defined by the ROC
method. These results are consistent with previously
published MCID estimates based on clinical experience
and a distribution-based approach using a small data set
[53]. SEM has been proposed as a useful method of
expressing the imprecision of an instrument and its re-
sponsiveness and was used in several studies [28,54]. In
our study SEM was 4.2 and was smaller than ROC and
mean change estimates of MCID-I. However SEM is
related to the minimal statistical detectable difference
and not to the individually perceived benefit from the
treatment. The ES of the TQ changes for the minimally
better group was 0.41. Thus using ES d = 0.5 as proposed
by Norman et al. would represent the most conservative
MCID-I estimate of all (Figure 3) [49]. Similarly to SEM,
ES also do not represent a clinically meaningful estimate
of MCID change as it provides no direct information
about the MCID and is a way of expressing the observed
change in a standardized way. The group, which reported
highly relevant improvement, had a mean reduction in
TQ of about −16.7 points and may be considered a “super
response” group. This closely corresponds to the ”super
response“ of 15 points in TQ proposed by Goebel et al.
[55] that was used in clinical studies [43].
Based on our results the MCID-I estimated as a ΔTQ
of −5 points seems an acceptable choice. This also
closely corresponds to the cut-off values proposed in the
past to interpret results of clinical studies and to define
a therapeutic success (response) [43,53,55]. A change of
−17 points would represent a “super response”, how-
ever more detailed analysis is needed to define the cut
off point for a ,,super response“. Calculation of the pro-
portion of patients who achieve this magnitude of relief,
i.e., -5 TQ points, would provide clinically relevant infor-
mation about the efficacy of the evaluated treatment[56]. By using MICD as a response criterion one can also
estimate the proportion of responders in each trial arm
and thus calculate the number of patients needed to
treat for further trials. This approach may be used com-
plementary to defining statistical significance of group
differences where in large samples even small changes in
mean scores can yield “statistically significant” results
that may be without clinical relevance.
Conclusions
MCID of the change in TQ score was found to be around
−5 points for improvement and +1 point for deterioration.
These results provide an orientation for what a clinically
meaningful change in the TQ score is. MCID may serve
as an orientation to interpret changes in individual
patients as well as in results of clinical trials. We investi-
gated the influence of baseline scores on MCID. The mag-
nitude of an important change depended on patient’s
baseline TQ scores. However, the role of other potential
influencing factors, e.g., duration or etiology of tinnitus
should also be investigated in further studies.
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